Drug name - Zelboraf

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8143271 HOFFMANN LA ROCHE NA
Jun, 2026

(3 years from now)

US7504509 HOFFMANN LA ROCHE Compounds and methods for development of Ret modulators
Oct, 2026

(4 years from now)

US7863288 HOFFMANN LA ROCHE NA
Jun, 2029

(6 years from now)

US8741920 HOFFMANN LA ROCHE Process for the manufacture of pharmaceutically active compounds
Jul, 2030

(7 years from now)

CN101223169A HOFFMANN LA ROCHE Pyrrolo[2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Jul, 2012

(10 years ago)

CN1925855A HOFFMANN LA ROCHE Compounds And Methods For Development Of Ret Modulators
Dec, 2024

(2 years from now)

CN1925855B HOFFMANN LA ROCHE Compounds And Methods For Development Of Ret Modulators
Dec, 2024

(2 years from now)

CN102206216B HOFFMANN LA ROCHE Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor
Jun, 2026

(3 years from now)

CN102603581A HOFFMANN LA ROCHE Pyrrolo [2,3-B] Pyridin Derivative As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

CN102603581B HOFFMANN LA ROCHE Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor
Jun, 2026

(3 years from now)

CN101243084B HOFFMANN LA ROCHE Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor
Jun, 2026

(3 years from now)

CN102206216A HOFFMANN LA ROCHE Pyrrolo [2, 3-B] Pyridine Derivate As Protein Kinase Inhibitor
Jun, 2026

(3 years from now)

CN101243084A HOFFMANN LA ROCHE Pyrrolo[2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

CN104910150B HOFFMANN LA ROCHE Method For Preparing Medicine Active Compound
Jul, 2030

(7 years from now)

CN104910150A HOFFMANN LA ROCHE Method For Preparing Medicine Active Compound
Jul, 2030

(7 years from now)

CN102574799A HOFFMANN LA ROCHE Process For Manufacture Of Pharmaceutically Active Compounds
Jul, 2030

(7 years from now)

CN102574799B HOFFMANN LA ROCHE Method For Preparation Medicine Active Compound
Jul, 2030

(7 years from now)

CN103601725B HOFFMANN LA ROCHE Method For Preparing Medicine Active Compound
Jul, 2030

(7 years from now)

CN103601725A HOFFMANN LA ROCHE Method For Preparing Phrmaceutically Active Compounds
Jul, 2030

(7 years from now)

IN200704938P2 HOFFMANN LA ROCHE Pyrrolo[2,3-B] Pyridine Derivatives As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

IN284438B HOFFMANN LA ROCHE Pyrrolo[2,3-B] Pyridine Derivatives As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

EP1696920A2 HOFFMANN LA ROCHE Compounds And Methods For Development Of Ret Modulators
Dec, 2024

(2 years from now)

EP1696920B1 HOFFMANN LA ROCHE Compounds And Methods For Development Of Ret Modulators
Dec, 2024

(2 years from now)

EP1696920A4 HOFFMANN LA ROCHE Compounds And Methods For Development Of Ret Modulators
Dec, 2024

(2 years from now)

EP1696920B8 HOFFMANN LA ROCHE Compounds And Methods For Development Of Ret Modulators
Dec, 2024

(2 years from now)

EP2395004B1 HOFFMANN LA ROCHE Pyrrolo [2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

EP2395004A2 HOFFMANN LA ROCHE Pyrrolo [2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

EP2395004A3 HOFFMANN LA ROCHE Pyrrolo [2,3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Jun, 2026

(3 years from now)

EP1893612A1 HOFFMANN LA ROCHE Pyrrolo [2, 3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Feb, 2027

(4 years from now)

EP1893612B1 HOFFMANN LA ROCHE Pyrrolo [2, 3-B]Pyridine Derivatives As Protein Kinase Inhibitors
Feb, 2027

(4 years from now)

EP2462116A2 HOFFMANN LA ROCHE Process For The Manufacture Of Pharmaceutically Active Compounds
Jul, 2030

(7 years from now)

EP2462116B1 HOFFMANN LA ROCHE Process For The Manufacture Of Pharmaceutically Active Compounds
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818 HOFFMANN LA ROCHE NA Aug, 2026

(3 years from now)

US9447089 HOFFMANN LA ROCHE Compositions and uses thereof Jun, 2032

(9 years from now)

Drugs and Companies using VEMURAFENIB ingredient

Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
240MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.